An Early Phase 1 interventional study of Octreotide infusion and Saline infusion in Lymphatic Diseases and Chylothorax, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-30.
Sponsored by Rigshospitalet, Denmark · Early Phase 1, Interventional, and Treatment
This study aims to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. To study the effects of octreotide, the researchers conducted a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and other lymphatic disorders.
This study aimed to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. Chylothorax is a condition in which there is an accumulation of lymphatic fluid in the chest cavity, and the mechanism through which octreotide helps to resolve this condition is not well understood. It has been speculated that the drug may reduce lymph production, but this has not been directly demonstrated. To study the effects of octreotide on human lymphatic vessels, the investigators conducted two experiments: a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber, and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults, assessed by using plethysmography and near-infrared fluorescence imaging. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and to clarify the mechanism through which it acts. It is important to continue researching and developing effective treatments for chylothorax, as it can be a difficult condition to manage and may cause serious complications if left untreated.
47 studies on the registry are indexed under Lymphatic Diseases; 11 are open to participants now.
This study's enrollment of 16 is below the median of 30 across 31 interventional studies indexed under Lymphatic Diseases.
Browse Lymphatic Diseases studies →Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
* Healthy
Exclusion Criteria:
Drug: Octreotide infusion · Drug: Saline infusion
Drug: Octreotide infusion · Drug: Saline infusion
Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
Saline Infusion
Lymph rate
Propulsions /minute
Time frame: During infusion
Lymph Pressure
mmHg assessed by near-infra fluorescence imaging
Time frame: During infusion
Capillary filtration rate
assessed by plethysmography
Time frame: During infusion
Capillary filtration coefficiency
assessed by plethysmography
Time frame: During infusion
Isovolumetric pressure
assessed by plethysmography
Time frame: During infusion
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chylothorax
Rigshospitalet, Denmark